54. Ketamine with Paul Glue


This week’s episode features Paul Glue, professor of Psychiatry at the Dunedin School of Medicine, University of Otago, New Zealand.

With a vast experience in both academia and pharmaceutical industry, Paul Glue’s research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological and psychiatric disorders. He is also interested in psychopharmacology and the development of novel therapeutics for affective disorders. One of these novel substances that have dominated his career is ketamine for treatment-resistant depression. Professor Glue hopes that his development of oral ketamine (rather than intravenous) will bring ketamine treatment from the clinics “back to people’s bathrooms”.

Tune in to this episode to listen to a fascinating conversation between two great scientists about, well… Drug Science.



National Institute on Alcohol Abuse and Alcoholism


Electroconvulsive therapy (ECT)

NMDA glutamate receptor

Overexcitement and disinhibition
Dynamic Neurotransmitter Interactions in Alcohol Withdrawal
 by Paul Glue and David Nutt 


John Krystal

Treatment-resistant depression

Ketamine Assisted Psychotherapy

Montgomery-Asberg Depression Rating Scale

Douglas Pharmaceuticals

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression

Mechanisms of ketamine action as an antidepressant – P Zanos, T D Gould

Food and Drug Administration (FDA)

Medicines and Healthcare products Regulatory Agency

Good manufacturing practice (GMP)


QT interval 

The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation



Psychedelics Promote Structural and Functional Neural Plasticity – Ly et al.

Serotonin 2a receptor